Atsena Therapeutics, Inc. — Form D
Atsena Therapeutics, Inc. of DURHAM, NC, a company, filed a Form D exempt-offering notice with the SEC on 2023-10-02. The offering totals $32.0M, of which $24.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-10-02
- Form: D
- Accession: 0001811468-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $32.0M
- Amount sold: $24.5M
- Remaining: $7.5M
- Investors: 10
- Date of first sale: 2023-08-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-493532
Issuer
- Name: Atsena Therapeutics, Inc.
- CIK: 0001811468
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 8 DAVIS DRIVE, SUITE 300, DURHAM, NC, 27709
- Phone: 984-261-2001
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Shannon Boye | Director | Durham, NC |
| Michael Dial | Director | Durham, NC |
| James Healy | Director | Sunnyvale, CA |
| Elizabeth Leiderman | Executive Officer | Durham, NC |
| Benjamin Yerxa | Director | Fort Worth, TX |
| Norbert Riedel | Director | LUNENBURG, MA |
| Jacqueline Grant | Director | Durham, NC |
| Christina Isacson | Director | Durham, NC |
| Chris Carpenter | Director | Durham, NC |
| Joe Zakrzewski | Director | Durham, NC |
| Jennifer Wellman | Director | Durham, NC |
| Patrick Ritschel | Director | Durham, NC |
| Patrick Ritschel | Executive Officer | Durham, NC |
| Shannon Boye | Executive Officer | Durham, NC |
| Sanford Boye | Executive Officer | Durham, NC |
Other filings by this issuer (3)
More